CeriBell Inc. (CBLL)
NASDAQ: CBLLHealth CareBiotechnology: Electromedical & Electrotherapeutic ApparatusUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CBLL stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.06B
- EPS (TTM)
- -$1.95
- Dividend yield
- None
- 52-week range
- 14.87 – 28.89
- Day range
- 25.58 – 27.45
- Volume / Avg
- 655.91K / 452.64K
- Beta
- —
- Shares outstanding
- 38.84M
52-week range
CBLL stock today
Shares of CeriBell (CBLL) finished higher on Nov 20 at $27.39, a gain of 6.37% or $1.64 per share, versus the S&P 500's 3.70% decline. Shares are 5.2% below their 52-week high of $28.89, set on Nov 3, 2026 and 84.2% above the 52-week low of $14.87, near the top of the past year's range. CBLL is up 24.9% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 79.5%.
CeriBell has posted a net loss over the last twelve months (EPS of -$1.95), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About CeriBell
Company profileCeriBell, Inc. operates as a medical technology company in the United States. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting.
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CEO
- Dr. Xingjuan Chao Ph.D.
- Headquarters
- Sunnyvale, CA
- Employees
- 327
- IPO year
- 2024
- Website
- ceribell.com
Financial highlights
Full financialsIn fiscal 2025, CeriBell generated $89.1 million in revenue, up 36.1% from fiscal 2024, its 2nd consecutive year of revenue growth. CeriBell reported a net loss of $53.4 million, compared with a loss of $40.5 million a year earlier. Gross margin was 87.9% (up from 86.7%) and operating margin -65.6%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | $89.06M | $65.44M | $45.23M |
| Growth | +36.09% | +44.71% | — |
| Net income | $-53.41M | $-40.45M | $-29.46M |
| EPS (diluted) | $-1.46 | $-3.39 | $-5.56 |
Analyst forecast
ForecastConsensus (8 analysts)
strong_buy
Avg. price target
$31.57+15.26%
- Strong buy 1
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 3, 2026
- EPS actual vs est.
- $-0.55 vs $-0.50
- Surprise
- -10.00%
CBLL news
All CBLL news- CeriBell Consensus Price Target Raised 10.5% to $32.20Nasdaq
- CeriBell Posts Higher Q3 Loss Of $21 Mln With New Launch Expenses; Stock DownNasdaqCBLL, WSO.B
- CeriBell outlines $115M-$117M 2026 revenue, while launching delirium monitoring and previewing Omni for 2027Seeking Alpha
- CeriBell GAAP EPS of -$0.55 misses by $0.04, revenue of $29.3M beats by $0.14MSeeking Alpha
- Ceribell Reports Third Quarter 2026 Financial ResultsGlobeNewswire
- CeriBell Launches Delirium Detection System To ICU Brain Monitoring Platform With Medicare BackingNasdaqCBLL, BF.A
- Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring SolutionGlobeNewswire
- Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services ForumGlobeNewswire
CeriBell peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CNMDCONMED Corporation | 46.56 | +0.39% | $1.39B | vs CBLL |
| INMDInMode Ltd. | 12.42 | -2.20% | $714.70M | vs CBLL |
| CVCapsoVision Inc. | 6.11 | -3.17% | $327.56M | vs CBLL |
| ELMDElectromed Inc. | 22.98 | -1.20% | $187.84M | vs CBLL |
| FOCLEDAP TMS S.A. ADR | 2.61 | -7.45% | $123.25M | vs CBLL |
| VANIVivani Medical Inc. | 1.14 | +4.59% | $102.83M | vs CBLL |
| STXSStereotaxis Inc. | 0.9422 | -6.71% | $95.03M | vs CBLL |
| HSDTSolana Company Class A | 1.49 | -10.24% | $93.70M | vs CBLL |
Indexes, lists and sector
CeriBell stock FAQ
What is CeriBell's stock price today?
CBLL last traded at $27.39 as of Nov 20, 4:00 PM EST, up 6.37% on the day. Prices are delayed at least 15 minutes.
Who is CeriBell's CEO?
Dr. Xingjuan Chao Ph.D. is the chief executive officer of CeriBell Inc., which has about 327 employees.
What is the CBLL 52-week high?
The 52-week high for CBLL is $28.89 and the 52-week low is $14.87. The stock is currently 5.2% below its high.